Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687239 | 0.78 | AKR1B1 (0.41) | AKR1B1PTGS2PTGDR2SMN1; SMN2GAA | |
| SCHEMBL17681854 | 0.78 | AKR1B1 (0.41) | AKR1B1PTGS2PTGDR2SMN1; SMN2GAA | |
| SCHEMBL22870401 | 0.77 | AKR1B1 (0.43) | AKR1B1PTGS2KDM4EAGBL2PTGDR2 | |
| SCHEMBL29607174 | 0.77 | AKR1B1 (0.43) | AKR1B1PTGS2KDM4EAGBL2PTGDR2 | |
| SCHEMBL24495428 | 0.75 | ALDH1A1 (0.41) | AKR1B1PTGS2KDM4EPTGDR2SMN1; SMN2 | |
| SCHEMBL29686660 | 0.75 | ALDH1A1 (0.41) | AKR1B1PTGS2KDM4EPTGDR2SMN1; SMN2 | |
| SCHEMBL17681792 | 0.73 | AKR1B1 (0.46) | AKR1B1PTGS2KDM4EAGBL2GABRR1 | |
| SCHEMBL940253 | 0.72 | AKR1B1 (0.59) | AKR1B1KDM4EGABRR1 | |
| Hydrochloric Acid SCHEMBL7356687 | 0.71 | AKR1B1 (0.57) | AKR1B1KDM4EGABRR1 | |
| SCHEMBL18301686 | 0.70 | AKR1B1 (0.57) | AKR1B1PTGS2KDM4EPTGDR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204374-B1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-04-03 | — | — | EP | disclosed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-9975873-B2 | Isoindoline derivatives | UCB BIOPHARMA SPRL (BE) | 2018-05-22 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313677-A1 | Isoindoline Derivatives | UCB BIOPHARMA SPRL (BE) | 2017-11-02 | — | — | US | disclosed |
| WO-2016055482-A1 | ISOINDOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313677-A1 | Isoindoline Derivatives | OPRD1, ADRA1D, DRD2 | AKR1B1 975/4885PTGS2 1347/4885KDM4E 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.